Positions

Post-Doctoral Research Fellows

The laboratory of Carlos L. Arteaga, M.D., at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern is recruiting Postdoctoral Research Fellows.

Projects include:

  • Discovery of mechanisms of resistance to antiestrogen therapy in breast cancer
  • Genomic profiling of drug-resistant ER+ and triple negative breast cancer
  • Mechanism of action of gain of function oncogenes in breast cancer and their use as predictive biomarkers of response (and resistance) to targeted therapies
  • Mechanisms of action of and resistance to rational combinations of targeted therapies in breast cancer (focus on PI3K/AKT, mutant ERBB receptors, ERa, FGFR, CDK4)

Methods include CRISPR screens, gain-of-function ORF whole genome screens, next gen DNA sequencing, single cell RNAseq, structural modeling, small animal functional imaging, molecular profiling of primary tumors (whole exome, RNA-seq), statistical analysis, and discovery focused on studies with cell lines and xenografts (from cell lines and patient-derived) using conditional shRNAs and targeted therapies in clinical development both in vitro and in vivo and primary tumors from patients in clinical trials with targeted therapies.

Relevant recent publications that apply to these topics include:

  • Mayer IA, Abramson VG, Estrada MV, Sanders ME, Formisano L, Balko JM, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. Phase Ib study of alpelisib (BYL719, a PI3Ka-specific inhibitor) with letrozole in ER+/HER2-negative metastatic breast cancer. Clin. Cancer Res. 2016 Apr 28. pii: clincanres.0134.2016 [Epub ahead of print]
  • Balko JM, Schwarz LJ, Cook RS, Estrada MV, Giltnane JM, Sanders ME, Sánchez V, Wang K, Combs S, Hicks D, Pinto JA, Landis MD, Chang JC, Doimi FD, Gómez H, Rimm DL, Yelensky R, Miller VA, Stephens PJ, Arteaga CL. Triple negative breast cancers with amplifications of JAK2 at the 9p24 loci exhibit JAK2-specific dependence. Sci. Transl. Med. 2016 Apr 13;8(334):334ra53 doi: 10.1126/scitranslmed.aad3001
  • Joseph JD, Darimont B, Zhou W, Arrazate A, Walter K, Blake RA, Nonomiya J, Guan Z, Young A, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee K-J, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalf C, Hager JH. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. eLife 2016 Jul 13;5. pii: e15828. doi: 10.7554/eLife.15828. PMID: 27410477
  • Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee K-m, Hutchinson KE, Witkiewicz A, Moore PD, Estrada MV, Sánchez V, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. RNA interference kinome-wide screen reveals a novel role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017 Mar 1. pii: canres.2653.2016. doi: 10.1158/0008-5472.CAN-16-2653. [Epub ahead of print]
  • Hanker AB, Red-Brewer M, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL. An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer. Cancer Discov. 2017 Mar 8. pii: CD-16-1431. doi: 10.1158/2159-8290.CD-16-1431. [Epub ahead of print]
  • Hanker AB, Estrada VM, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson D, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL. Extracellular matrix (ECM)/integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+ breast cancer. Cancer Res. 2017 Apr 10. pii: canres.2808.2016. doi: 10.1158/0008- 5472.CAN-16-2808. [Epub ahead of print]
  • Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, González-Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano AL, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak I, Arteaga CL. An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression. J. Natl. Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065
  • Hanker AB, Garrett JT, Estrada MV, Moore PD, Langley E, Singh S, Kim PS, Frampton G, Sanford E, Owen P, Becker J, Groseclose MR, Castellino S, Heikki J, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown V, Baselga J, Piccart M, Sotiriou C, Arteaga CL. HER2- overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin. Cancer Res. 2017 Apr 5. pii: clincanres.2287.2016. doi: 10.1158/1078-0432.CCR-16-2287. [Epub ahead of print]
  • Guerrero-Zotano AL, Arteaga CL. Neoadjuvant trials in estrogen receptor-positive breast cancer: A tool for acceleration of drug development and discovery. Cancer Discov. 2017 Jun;7(6):561-574. doi: 10.1158/2159-8290.CD-17-0228. Epub 2017 May 11. PMID: 28495849
  • Formisano L, Stauffer Km, Young CD, Bhola NE, Jansen VM, Guerrero AL, Jansen VM, Estrada MV, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde J-G, Mayer IA, Sanders ME, Dugger TC, Bianco R, Stricker TP, Arteaga CL. Association of FGFR1 with ERa maintains ligand independent ER transcription and mediates resistance to estrogen deprivation in breast cancer. Clin. Cancer Res. 2017 Jul 27. pii: clincanres.1232.2017. doi: 10.1158/1078-0432.CCR-17-1232. [Epub ahead of print] PMID 28751448
  • Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sánchez V, Gonzalez-Ericsson P, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson VG, Gómez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short term estrogen suppression reveals alterations associated with endocrine resistance. Sci. Transl. Med. 2017 Aug 9; 9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. PMID 28794284
  • Lee K-m, Giltnane JM, Balko, JM, Schwarz LJ, Guerrero AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Fesik SW, Arteaga CL. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells through regulation of mitochondrial oxidative phosphorylation. Cell Metabolism 2017 Oct 3;26(4):633-647.e7. doi: 10.1016/j.cmet.2017.09.009
  • Croessmann S, Sheehan JH, Lee K-m, Sliwoski G, He J, Nagy R, Riddle D, Leelatian N, Mayer IA, Irish J, Balko JM, Lanman R, Miller V, Cantley LC, Meiler J, Arteaga CL. PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence and are exquisitely sensitive to PI3Ka inhibitors. Clin. Cancer Res. 2017 Dec 28. pii: clincanres.2141.2017. doi: 10.1158/1078-0432.CCR-17-2141. [Epub ahead of print]
  • Guerrero-Zotano AL, Stricker TP, Hutchinson KE, Stover DG, Lee K-m, Formisano L, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Gavilá J, Fidalgo A, Lluch A, Llombart A, Michiel S, André F, Arnedos M, Ruiz A, Arteaga CL. Estrogen receptor-positive (ER+) breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors. Clin. Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078- 0432.CCR-17-2904. Epub 2018 Mar 26
  • Croessman S, Formisano L, Nagy G, Mathew A, Bernicker EH, Cristofanilli M, He J, Dugger T, Cutler RJ, Lalani AS, Avogadri-Connors F, Miller VA, Lanman R, Arteaga CL. Inhibition of mutant HER2 with neratinib results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells. Submitted
  • Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon M, Croessmann SE, González-Ericsson PI, Sanders ME, Balko JM, Avogadri-Connors F, Cutler RE, Alani AS, Bryce R, Auerbach A, Arteaga CL. Extended adjuvant neratinib and fulvestrant block ER/HER2 crosstalk and maintain complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial. Submitted
  • Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker AB, Guerrero-Zotano A, Guo Y, GonzalezEricsson P, Lee K-m, Nixon MJ, Schwarz LJ, Sanders ME, Sudhan DR, Dugger TC, Rocha Cruz M, Behdad A, Cristofanilli M, Bardia A, O’Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Submitted

Applicants with a Ph.D., M.D., or M.D./Ph.D. and a strong background in molecular & cell biology and genomics with a strong interest in translational research are encouraged to apply.

Please forward your CV and names of three references to:

Carlos L. Arteaga, M.D.
Director, UTSW Harold C. Simmons Cancer Center
5323 Harry Hines Blvd.
Dallas, TX 75390-8590
carlos.arteaga@utsouthwestern.edu

Tel. 214-648-1677
Fax 214-648-7084

Assistant: Paula Ribeiro
Tel. 214-648-7439
Fax 214-648-7084